MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
3.180
-0.010
-0.31%
Opening 10:06 07/10 EDT
OPEN
3.180
PREV CLOSE
3.190
HIGH
3.190
LOW
3.180
VOLUME
2.92M
TURNOVER
--
52 WEEK HIGH
4.175
52 WEEK LOW
1.100
MARKET CAP
819.46M
P/E (TTM)
-53.1773
1D
5D
1M
3M
1Y
5Y
1D
Esperion shareholders approve merger with Essence Parent Inc.
TipRanks · 2d ago
Esperion stockholders approve merger agreement at special meeting
PUBT · 2d ago
Weekly Report: what happened at ESPR last week (0629-0703)?
Weekly Report · 4d ago
Weekly Report: what happened at ESPR last week (0622-0626)?
Weekly Report · 06/29 09:17
Weekly Report: what happened at ESPR last week (0615-0619)?
Weekly Report · 06/22 09:19
Top Esperion Executives Quietly Unload a Wave of Shares
TipRanks · 06/19 02:06
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
Barchart · 06/17 14:25
Esperion clears key U.S. antitrust hurdle for merger
TipRanks · 06/16 21:03
More
About ESPR
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cardiometabolic and rare/orphan disease therapies. It markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels who are at risk of cardiovascular disease and nasal spray, loop diuretic for the treatment of edema associated with congestive heart failure, and hepatic and renal disease. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. NEXLETOL is a first-in-class ACLY inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors. NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and cholesterol absorption in the intestine. Its Enbumyst is the FDA-approved nasal spray loop diuretic.

Webull offers Esperion Therapeutics Inc stock information, including NASDAQ: ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.